
Ultivue, Inc.: Pioneering commercial physical and biological research since 2015.
Founded in 2015, Ultivue, Inc. is dedicated to advancing commercial physical and biological research. The company's core mission is to empower scientists in the development of precision cancer therapies through innovative technologies. Ultivue offers ultrasensitive InSituPlex® assays and AI-driven spatial analysis tools that enable rapid, high-confidence insights into tissue samples. Their primary market focus is on providing solutions for profiling the immune landscape in tissues, thereby turning complex biological data into actionable insights.
Notable figures affiliated with Ultivue include leading scientists and industry experts who contribute to its pioneering research and development efforts. The company has attracted significant investment from prominent venture capital firms, bolstering its growth and innovation capacity. Key achievements include the successful deployment of InSituPlex® technology in numerous research settings, significantly accelerating the pace of cancer therapy development. Ultivue's impact is evident in its ability to provide researchers with unprecedented clarity and speed in biomarker analysis, ultimately enhancing the precision and effectiveness of cancer treatments.

Altos Labs
altoslabs.com

Zinnia Technologies
zinniatv.com

ClearLight Biotechnologies

Upstream Bio
upstreambio.com

Illuminare Biotechnologies
illuminarebio.com

Tuktu Care
tuktu.ca

Endolytix

Vivo
teamvivo.com

Phenomix Sciences

Uvax Bio
uvaxbio.com

Affini-T Therapeutics
affinittx.com

Cambridge Technologies

Ontera
ontera.bio

Limelight Bio

Xylyx Bio
xylyxbio.com
Companies similar to Ultivue include Altos Labs, Zinnia Technologies, ClearLight Biotechnologies and Upstream Bio.
Ultivue was founded in 2015.
Ultivue's headquarters is located in Cambridge, MA, US.
Ultivue's most recent funding round was for $50M (USD) in April 2021.
As of Apr 27, 2021, Ultivue has raised a total of $107.3M (USD).
Ultivue has 56 employees as of Feb 5, 2024.